Reach Pharmaceuticals Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
30 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEXRAZOXANE-REACH dexrazoxane 500 mg powder for injection for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEXRAZOXANE-REACH dexrazoxane 250 mg powder for injection for infusion vial.
-
Prescription medicine registrationActive ingredients: dexrazoxane.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FUROSEMIDE-REACH furosemide 20 mg/2 mL solution for injection ampoule.
-
Prescription medicine registrationActive ingredients: furosemide.
-
-
Australian Public Assessment Report (AusPAR)Nelarabine-reach (nelarabine) was approved to treat relapsing /refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for NELARABINE-REACH nelarabine 250 mg/50 mL solution for infusion vial.
-
Prescription medicine decision summaryNelarabine-Reach (nelarabine) is an anti-cancer drug approved for the treatment of relapsing/refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma.
-
Prescription medicine registrationActive ingredients: nelarabine.